CORMEDIX INC. (NYSEMKT:CRMD) Files An 8-K Other EventsItem 8.01. Other Events.
CORMEDIX INC. (NYSEMKT:CRMD) Files An 8-K Other Events
On April 20, 2017, we issued a press release to provide an update for our ongoing U.S. Phase 3 “LOCK-IT 100” clinical study of our lead product Neutrolin®.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
Exhibit No.
Description
99.1
Press release dated April 20, 2017.
About CORMEDIX INC. (NYSEMKT:CRMD)
CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation. CORMEDIX INC. (NYSEMKT:CRMD) Recent Trading Information
CORMEDIX INC. (NYSEMKT:CRMD) closed its last trading session 00.00 at 1.19 with 141,887 shares trading hands.
CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation. CORMEDIX INC. (NYSEMKT:CRMD) Recent Trading Information
CORMEDIX INC. (NYSEMKT:CRMD) closed its last trading session 00.00 at 1.19 with 141,887 shares trading hands.
